Identifying Patients at Risk: Detecting Early Interstitial Lung Disease & Predicting Progression to Enable Earlier Intervention
- Examining how interstitial lung abnormalities detected through screening imaging may represent the earliest stages of fibrotic lung disease and identifying the clinical features that predict progression to clinically significant ILD
- Exploring emerging circulating biomarkers, genetic risk factors, and proteomic signatures associated with disease severity, mortality risk, and likelihood of progression
- Understanding how early identification of high-risk patients could enable earlier therapeutic intervention and more efficient recruitment into ILD clinical trials